In a recent appearance on the 'Money Movers' podcast, Pfizer CEO Albert Bourla said that recent policy measures and growing competition have driven average list prices for the company’s top 10 U.S. products down by 3.5% year-over-year in 2025. Bourla attributed part of that decline to the expanded use of biosimilars and generics under the Inflation Reduction Act, which imposed price negotiation for more products. He also highlighted Pfizer’s investments in artificial intelligence, noting that AI-driven target identification and trial-enrichment models have already accelerated lead candidate selection by 20%, reducing time to Phase I trials from an average of 12 months to 9.5 months in the past 18 months. Bourla projected that continued AI deployment across R&D could cut late-stage development costs by up to 15% by 2028.

Pfizer announced the sale of its 11.7% stake in ViiV Healthcare to a consortium led by Shionogi for $1.875 billion, marking a strategic step to redeploy capital toward internal oncology and rare-disease pipelines. The disposition closes in Q1 2026 and is expected to boost Pfizer’s cash flow by $1.8 billion, which management plans to allocate to late-stage trials of a next-generation mRNA influenza candidate and expansion of manufacturing capacity. The company said the divestiture reduces its exposure to HIV royalties by approximately $400 million annually, while preserving a collaboration agreement for future co-development of novel antiretroviral compounds.

Pfizer’s non-oncology segment is projected to grow mid-single digits in Q4 2025, driven by 12% volume growth in the anticoagulant Eliquis and steady demand for its pneumococcal vaccine, Prevnar 13, which saw 8% year-over-year uptake in emerging markets. Management cautioned that COVID-19 vaccine revenues will continue to decline, with Q4 sales expected at $250 million versus $1.3 billion in the prior-year quarter. Excluding COVID-19, core non-oncology sales are forecast to rise by approximately 5.5%, supported by market share gains in inflammation and cardiology portfolios across North America and Europe.